Atazanavir–bilirubin interaction: a pharmacokinetic–pharmacodynamic model

Purpose: The aim of this work was to analyze the atazanavir–bilirubin relationship, using a new mathematical approach to pharmacokinetic–pharmacodynamic models, for competitive drug interactions based on Michaelis–Menten equations.

Patients and methods: Because atazanavir induces an increase of plasma bilirubin levels, in a concentration-dependent manner, we developed a mathematical model, based on increments of atazanavir and bilirubin concentrations at steady state, in HIV infected (HIV+) patients, and plotted the corresponding nomogram for detecting suboptimal atazanavir exposure.

Results: By applying the obtained model, the results indicate that an absolute value or an increment of bilirubin at steady state below 3.8 µmol/L, are predictive of suboptimal atazanavir exposure and therapeutic failure.

Conclusion: We have successfully implemented a new mathematical approach to pharmacokinetic–pharmacodynamic model for atazanavir–bilirubin interaction. As a result, we found that bilirubin plasma levels constitute a good marker of exposure to atazanavir and of viral suppression.

Keywords: atazanavir, bilirubin, HIV/AIDS, pharmacodynamics, pharmacokinetics

Introduction
Atazanavir ([ATZ] REYATAZ®; Bristol-Myers Squibb, New York, NY, USA), an antiretroviral drug belonging to protease inhibitor (PI) class, is widely used to treat infection of human immunodeficiency virus (HIV)/AIDS and to prevent viral replication by selectively binding to viral proteases and blocking proteolytic cleavage of protein precursors. Given the specificity of its target, there is a risk for the development of viral resistance and, consequently, therapeutic failure.1

The reasons for this therapeutic failure are complex and include the incomplete adherence to therapy and other pharmacokinetic factors. Because of this, therapeutic drug monitoring (TDM) may be used alongside other diagnostic techniques to achieve optimal therapeutic efficacy with minimal toxicity and viral resistance.2,3

Pharmacokinetic differences contribute to variability and frequency of suboptimal antiretroviral exposure.4 In this way, TDM can be used to rule out subtherapeutic drug levels resulting from malabsorption, drug interactions, poor adherence, or increased drug metabolism or clearance.5 The TDM of protease-inhibitor drugs (PI) includes the study of plasma levels that correlate with clinical failure as one of the most important targets.6–8

Currently, the treatment guidelines for ATZ recommend a minimal effective concentration (MEC) of 0.2 µmol/L for successful viral suppression, and an upper
limit of <1.1 μmol/L, because this last recommendation has been associated with a high risk of increased unconjugated bilirubin and incidence of hyperbilirubinemia.5–9,11

We also know that all patients treated with ATZ exhibit a concentration-dependent increase of unconjugated bilirubin and total bilirubin levels (BILs), attributed to a concentration-dependent inhibition of UGT1A1 by ATZ. In contrast, similar direct relationships between ATZ concentrations and virological outcome have not yet been demonstrated.12–15

At this point, a pharmacokinetic–pharmacodynamic (PK–PD) model could be applied to describe the quantitative relationships between the response intensity of a biomarker or surrogate marker (increase in bilirubin plasma levels) and drug dose applied (ATZ plasma levels). This model has two components: a pharmacokinetic model, which will characterize the concentration of ATZ in blood or plasma; and a pharmacodynamic model, which will characterize the pharmacological effect, BIL increase, in this PK–PD drug-interaction based model.16,17

Finally, many authors have suggested that BIL may be used as a marker of adherence to ATZ therapy, exposure, and possible therapeutic outcome.9,18,19 However, despite having nomograms for the calculation of exposition to ATZ based on the turnover concept and indirect response model, which support the conventional model in this area,20 the data obtained by applying our present model were not consistent with those obtained by applying nomograms published by other authors.9,18–20

With the above in mind, this work was aimed at developing a new mathematical approach for a competitive-interaction PK–PD model of the ATZ–bilirubin interaction, based on Michaelis–Menten equations, and plotting of the corresponding ATZ–BIL nomogram for predictive detection of ATZ concentrations below MEC and for nonadherence.

Methods

We conducted a retrospective study by reviewing patients treated with ritonavir-boosted ATZ (ATZ-r), to evaluate ATZ-related BIL elevation, as an adherence and exposure marker, for treatments with ATZ.

Patients and sample data

The sample consisted of 47 HIV-infected Hispanic adult outpatients, recruited from the Hospital Clínico Universitario “Lozano Blesa,” Zaragoza, Spain, who were taking antiretroviral therapy (ART), were being managed at a public ART delivery site in Zaragoza, and who had initiated ART 6–12 months prior to starting the study, which was conducted between September 2011 and April 2012. Patient demographics are shown in Table 1.

The HIV-infected outpatients were taking ATZ-r 300/100 mg, once daily, for at least 6 months, in combination with two nucleoside reverse transcriptase inhibitors (NRTIs) or one NRTI plus one nucleotide reverse transcriptase inhibitor, with combinations that included emtricitabine/tenofovir, lamivudine, tenofovir, and nevirapine, according to the Spanish guidelines for choosing ART (Gesida21) (Table 1).

Data of ATZ-r treatments, BILs, viral load (VL), and clinical details were collected from pharmacy dispensing, medical history, and laboratory records.

For the outcome, we chose to look at VL level at four thresholds: VL < 50 copies/mL, VL = 50–1,000 copies/mL, 5,000 > VL > 1,000 copies/mL, and VL > 5,000 copies/mL. The last two thresholds were chosen to reflect the World Health Organization (WHO) criteria for prevention of HIV drug resistance (<1,000 copies/mL) and treatment failure (<5,000 copies/mL) and the first, VL < 50 copies/mL, because pharmacological response correlates very closely with this value.22–25

PK–PD model building

The pharmacokinetics of the ATZ and its BIL response is described by a competitive drug-interaction model, based on Michaelis–Menten kinetics, where hyperbilirubinemia is attributed to a concentration-dependent ATZ inhibition of UGT1A1, the enzyme responsible for bilirubin and ATZ conjugation (Figure 1).

This model describes the influence of two or more drugs acting on the same enzyme and predicts the combined effects of more than one drug, being the analysis of changes

Table 1 Clinical characteristics and antiretroviral-drug status of the patients

<table>
<thead>
<tr>
<th>Patient characteristics (n = 47)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Atazanavir-r</td>
</tr>
<tr>
<td>Women</td>
</tr>
<tr>
<td>Age (years) ≥ 40.1 (8.5)</td>
</tr>
<tr>
<td>Weight (kg) ≥ 60.7 (13.2)</td>
</tr>
<tr>
<td>FTC/TDF</td>
</tr>
<tr>
<td>NVP</td>
</tr>
<tr>
<td>3TC</td>
</tr>
<tr>
<td>TDF</td>
</tr>
</tbody>
</table>

Note: All data expressed as mean value (SD), except for Women and antiretroviral-drug percentages.
Abbreviations: TDF, tenofovir; FTC, emtricitabine; 3TC, lamivudine; NVP, nevirapine; SD, standard deviation.
in the velocity of reaction that occur when the drugs are used combined versus separately at steady state (SS), the general approach to the study of these interactions.\textsuperscript{12–15,26–28}

Once the SS was reached, we quantified the ATZ-bilirubin interaction by applying the mathematical model, as follows:

Deriving Michaelis–Menten’s equation,\textsuperscript{26}
\[ V = \frac{K_{\text{cat}} E_0 C}{K_m + C}, \]
for bilirubin and ATZ, we have
\[ \frac{dV_{\text{ATZ}}}{dC_{\text{ATZ}}} = K_{\text{cat}}^{\text{ATZ}} E_0 K_m^{\text{ATZ}} \]
and
\[ \frac{dV_{\text{BIL}}}{dC_{\text{BIL}}} = K_{\text{cat}}^{\text{BIL}} E_0 K_m^{\text{BIL}} \]
at SS, when
\[ dV_{\text{ATZ}} = dV_{\text{BIL}}, \]
then we have
\[ \Delta[\text{ATZ}]_{\text{ss}} = \frac{K_{\text{cat}}^{\text{BIL}} K_m^{\text{BIL}}}{K_{\text{cat}}^{\text{ATZ}} K_m^{\text{ATZ}}} \Delta[\text{BIL}]_{\text{ss}} \]
and
\[ \frac{\Delta[\text{ATZ}]_{\text{bas}}}{\Delta[\text{ATZ}]_{\text{ss}}} = \frac{\Delta[\text{BIL}]_{\text{bas}}}{\Delta[\text{BIL}]_{\text{ss}}}, \]
where \( V \) = glucuronidation reaction rate for bilirubin and ATZ, respectively; \( E_0 \) = UGT1A1 enzyme concentration; \( K_m \) = Michaelis–Menten constant for bilirubin and ATZ, respectively; and \( K_{\text{cat}} \) = turnover number for bilirubin and ATZ, respectively.

Therefore, ATZ and BIL increase plasma levels (\( \Delta[\text{ATZ}] \) and \( \Delta[\text{BIL}] \), respectively) of each other in a concentration-dependent manner and allow us to calculate BIL and ATZ increases at SS by using a simple principle of direct proportionality (Equation 1).

Accordingly, \( \Delta[\text{BIL}]_{\text{ss}} \) and \( \Delta[\text{ATZ}]_{\text{ss}} \) values to determine the risk of underexposure and/or antiviral toxicity can be calculated according to Equation 1 by using bibliographic data for MEC and for the minimal plasmatic concentration at SS (\( C_{\text{min ss}} \)). Because the latest data (\( C_{\text{bas}} \)) are exponential in nature, we used the geometric instead of arithmetic mean for calculations.

The pharmacokinetic characteristics of ATZ are shown in Table 2.

\section*{Results}
We obtained a mean value for BIL increase at SS (\( \Delta[\text{BIL}]_{\text{ss}} \)) equal to 17.1 \( \mu \text{mol/L} \), from 10.3 to 28.9 \( \mu \text{mol/L} \), related to a theoretical \( C_{\text{min ss}} \) equal to 0.9 \( \mu \text{mol/L} \) (Table 3).

Substituting into Equation 1 with the following data:
\begin{itemize}
  \item \( \Delta[\text{ATZ}]_{\text{ss}} = 0.9 \, \mu \text{mol/L} \); (as the result of \( C_{\text{min ss}} \))
  \item \( \Delta[\text{BIL}]_{\text{ss}} = 17.1 \, \mu \text{mol/L} \); (as the result of \( C_{\text{bas}} = 28.9 \, \mu \text{mol/L} \) minus \( \Delta[\text{ATZ}]_{\text{ss}} = 0.9 \, \mu \text{mol/L} \)).
  \item \( \Delta[\text{BIL}]_{\text{ss}} = 0.2 \, \mu \text{mol/L} \) (MEC of ATZ),
\end{itemize}
we obtained: \( \Delta[\text{ATZ}]_{\text{ss}} = 3.8 \, \mu \text{mol/L} \) and \( \Delta[\text{ATZ}]_{\text{ss}} = 0.2 \, \mu \text{mol/L} \).

Thus, 3.8 \( \mu \text{mol/L} \) is the lowest absolute \( \Delta[\text{BIL}]_{\text{ss}} \) value (obtained from \( \Delta[\text{BIL}]_{\text{ss}} = 3.8 \), when \( \Delta[\text{BIL}]_{\text{ss}} = 0 \)) and the lowest increment of BIL (obtained from \( \Delta[\text{BIL}]_{\text{ss}} = 3.8 \), when \( \Delta[\text{BIL}]_{\text{ss}} = 0 \)), to which \( C_{\text{min ss}} \) is above 0.2 \( \mu \text{mol/L} \) (MEC).
Accordingly, BIL_{\text{ss}} levels can be predicted at the MEC of ATZ (0.2 μmol/L) for various BIL_{\text{bas}} values. In this way, the resulting nomogram was obtained by putting “i” value pairs of BIL_{ss} and BIL_{bas} in the following equation:

\[ \Delta[BIL]_{\text{ss}} = [BIL]_{\text{ss, i}} - [BIL]_{\text{bas, i}} = 3.8 \mu\text{mol/L}, \quad [2] \]

where 3.8 μmol/L is both the lowest absolute BIL_{ss} value and the lowest increment of BIL, in order to achieve a C_{\text{max,ss}} ATZ above 0.2 μmol/L (MEC) (Figure 2).

On the other hand, and for clinical outcome proposals, we found that 87.2% of patients had VL < 50 copies/mL, 6.4% had VL = 50–1,000, 0% had 1,000 < VL < 5,000 copies/mL, and the remaining 6.4% had VL ≥ 5,000 copies/mL; and regarding BIL_{bas}, 4.4% of patients had BIL_{bas} < 3.8 μmol/L, while another 38% had BIL_{bas} > 30.2 μmol/L and high risk of potentially developing toxicity as jaundice eye and/or widespread.

Finally, a patient’s likelihood of having VL ≥ 5,000 copies/mL, the upper limit for absence of viral response according to Ledergerber et al, associated to BIL_{ss} ≤ 3.8 μmol/L, was higher than the likelihood associated to BIL_{ss} > 3.8 μmol/L (odds ratio [OR] = 42; 95% CI: 2.6 to 698.6; P = 0.0086) (Table 3).²⁹

### Table 2 Pharmacokinetics data of atazanavir (ATZ) at steady-state (SS)

<table>
<thead>
<tr>
<th>C_{\text{max,ss}} ATZ (μmol/L)</th>
<th>Geometric mean (CV %)</th>
<th>Mean (SD)</th>
</tr>
</thead>
<tbody>
<tr>
<td>T_{\text{ss}} (h)</td>
<td>Median</td>
<td>3.0</td>
</tr>
<tr>
<td>AUC (μmol - h/L)</td>
<td>Geometric mean (CV %)</td>
<td>65.4 (0.1)</td>
</tr>
<tr>
<td>T-half (h)</td>
<td>Mean (SD)</td>
<td>8.6 (2.3)</td>
</tr>
<tr>
<td>C_{\text{ss,ss}} ATZ (μmol/L)</td>
<td>Geometric mean (CV %)</td>
<td>0.9 (0.1)</td>
</tr>
<tr>
<td>Mean (SD)</td>
<td>1.2 (1.2)</td>
<td></td>
</tr>
</tbody>
</table>

Note: C_{\text{max,ss}} ATZ = The maximum/minimum concentration of ATZ at SS.

Abbreviations: AUC, area under the curve; SD, standard deviation; CV, coefficient of variation in %; h, hours.

With respect to the model for the quantification of ATZ-bilirubin interaction, previous studies have shown a positive correlation between ATZ exposure and hyperbilirubinemia that allow us to use BIL as a marker of ATZ exposure.²⁸⁻²⁰

Atazanavir and bilirubin are a substrate for the organic anion-transporting polypeptide (OATP)1B1, p-glycoprotein and UGT1A1, and atazanavir is mainly metabolized by CYP3A4 and UGT1A1. We assumed that induced hyperbilirubinemia by ATZ is due to the inhibition of bilirubin glucuronidation through UGT1A1 enzyme, not taking into consideration the influence from these other transporting and/or metabolizing enzymes, because they do not change the final end point (BIL increase).¹⁴,¹⁵,³⁰⁻⁴¹ Thus, we used BIL_{ss} as surrogate marker in a competitive interaction-based model, where bilirubin elimination through glucuronidation is inhibited by ATZ.

The final BIL_{ss} concentrations are predicted by increments of BIL (Δ[BIL]) plasma levels, from baseline levels to those after ATZ exposure, or by its absolute value, obtained from Δ[BIL] when BIL_{bas} = 0. In any case, the final BIL_{ss} are in direct dependence of the ATZ, being desirable to achieve a minimal BIL_{ss} concentration above 3.8 μmol/L for the proposed ATZ > 0.2 μmol/L.⁹

The present model is based on the study of the increments of ATZ and BIL, as model components, once the SS is reached. Thus, because this model is only dependent on concentration increments of interacting drugs (from drug concentration at the start of the interaction to drug concentration at SS) and is not a kinetic model, where the concentration is expressed as a function of time, the present model is only applicable once SS is reached, as for an adherence marker. Also, our model is independent of the pharmacokinetic model used, whereas the models based on the turnover concept, where a drug can inhibit or stimulate the production or elimination of a given variable, by contrast, are linked to a pharmacokinetic model and are applicable at any time with the plasma concentration of the drug as a function of time.¹⁹,²⁰

This turnover system is described with differential equations, where dR/dt is a function of K_{\text{on}} and K_{\text{off}} with R = response. In the drug induced inhibition models (I_{max})
models), with impact on the output ($K_{\text{out}}$), as for the conventional model in this interaction, we have:

$$\frac{dR}{dt} = K_{\text{in}} - K_{\text{out}} \left[ 1 - \left( \frac{I_{\text{max}} C_{\text{ATZ}}}{C_{\text{ATZ}} + IC_{50 \text{ATZ}}} \right) \right] R_{\text{BIL}}$$

where

$$H(C) = I(C) \text{def} = \left[ 1 - \left( \frac{I_{\text{max}} C_{\text{ATZ}}}{C_{\text{ATZ}} + IC_{50 \text{ATZ}}} \right) \right]$$. \[3\]

Here, “def = ” means that the quantity on the left is defined to the quantity on the right. The action of the drug takes place on $H(C)$, where $C = C(t)$ is the plasma concentration of the drug as a function of time (the drug function), taking place, in the case of ATZ-bilirubin interaction, via the loss term $K_{\text{out}}$ because ATZ inhibits and reduces the bilirubin elimination (response). In addition, these nonlinear models need previous estimates of $K_{\text{in}}$ (production rate of pharmacological response), $I_{\text{max}}$ (maximal drug induced inhibition), $IC_{50}$ (concentration at 50 percent of maximal drug induced inhibition) or, alternatively, to be viewed as linear function, as follows: $I(C) = 1 - \alpha C$, when $C << IC_{50}$, and the parameter $\alpha$ determined from the slope of the graph of AUC-R(D) versus log(D).\[42-44\]

Consequently, indirect response models have to establish a priori bounds on the response function ($R[i]$), on the peak time ($T_{\text{max}}$), and on the area under the curve (AUC-R).

Regarding the nomogram, as a result of applying the equations of our exposed mathematical model, based on changes of the reaction velocity of ATZ versus that of BIL, with the implicated enzyme UGT1A1, we obtained a relation of simple proportionality for the increments of ATZ and BIL plasma concentrations at SS (Equation 1), which we used to obtain the nomogram, illustrating the mentioned proportionality between $BIL_{\text{bas}}$ and $BIL_{\text{SS}}$ of patients on treatment with the same dose of ATZ. $BIL_{\text{SS}}$ data placed on the white area of the nomogram indicate an ATZ exposure over MEC (>0.2 μmol/L), while on the black area this means an ATZ exposure below MEC (<0.2 μmol/L). The minimal value of $BIL_{\text{SS}}$ for exposition to optimal ATZ concentration is 3.8 μmol/L.

Figure 2 The black area represents bilirubin steady state levels (BILss) associated with atazanavir (ATZ) exposure below minimal effective concentration (MEC), 0.2 μmol/L; and white area represents BILss associated with ATZ concentrations over MEC.
In the nomogram, BIL_{SS} values and its corresponding BIL_{bas} values are associated and, in order to predict an ATZ concentration above 0.2 (MEC), two separate measurements of bilirubin are needed (at baseline and at SS), except in the case of BIL_{SS} < 3.8 (minimal absolute value), where this one value alone is enough. At this point, the conventional model cannot provide the threshold minimum value data and, also, the areas corresponding to suboptimal exposure to ATZ do not match ours.\textsuperscript{20}

The second part of this work has been motivated by the potential benefits of BIL_{SS} as a measure of long-term adherence or exposure regarding virological outcomes. Given that ATZ increases BIL_{SS} in an exposure-dependent manner, we tested whether BIL_{SS} levels could be used as a surrogate marker of virological response to ATZ-based ART regimens.

Previous studies have shown a positive correlation between atazanavir exposure and hyperbilirubinemia but only, in some cases, hyperbilirubinemia have been correlated to virological failure.\textsuperscript{9,20} In this way, we have studied this relation between plasma concentrations of bilirubin and virological failure (VLF ≤ 5,000 copies/mL after 6 weeks of ART), having found an increased risk of virological failure in patients treated with ATZ and who had BIL_{SS} < 3.8 μmol/L (OR = 42). Thus, BIL_{SS} would be a practical marker of long-term ATZ exposure.

In short, the great majority of adherent patients treated with standard doses of ATZ-r have drug concentrations above MEC; however, our results support the routine use of atazanavir TDM, based on BIL_{SS}, for efficacy optimization of the treatments and for avoiding adverse events and drug interactions with the use of these drugs.

Nevertheless, more studies with larger number of patients with therapeutic failure are necessary, to achieve a better verification of the correlation between BIL_{SS} and VL.

**Conclusion**

The nomogram and mathematical model discussed in this paper allow us to calculate the patient exposure to ATZ plasma levels above 0.2 μmol/L and to assess the patient risk of virological failure based on data of BIL at SS and baseline, in a quick and easy way.

We can also conclude that there is a minimum BIL at SS, equal to 3.8 μmol/L, whatever the mathematical model used and different from zero, below which ATZ does not reach a minimal effective concentration; consequently, the risk of virological failure increases.

Thus, bilirubin constitutes a good marker of long-term exposure to ATZ and virological failure for patients being treated with this drug.

**Disclosure**

The authors report no conflicts of interest in this work.

**References**


Clinical Pharmacology: Advances and Applications

Publish your work in this journal

Clinical Pharmacology: Advances and Applications is an international, peer-reviewed, open access journal publishing original research, reports, reviews and commentaries on all areas of drug experience in humans. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use.

Submit your manuscript here: http://www.dovepress.com/clinical-pharmacology-advances-and-applications-journal

Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.